Trials / Completed
CompletedNCT04493281
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the single-dose bioequivalence of oral suspension and intravenous (IV) formulation of edaravone in the fasting state in healthy adult subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-1186 | Oral suspension |
| DRUG | MCI-186 | Intravenous formulation |
Timeline
- Start date
- 2019-03-22
- Primary completion
- 2019-04-21
- Completion
- 2019-05-09
- First posted
- 2020-07-30
- Last updated
- 2026-01-07
- Results posted
- 2024-01-18
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04493281. Inclusion in this directory is not an endorsement.